PL356802A1 - Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors - Google Patents

Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors

Info

Publication number
PL356802A1
PL356802A1 PL01356802A PL35680201A PL356802A1 PL 356802 A1 PL356802 A1 PL 356802A1 PL 01356802 A PL01356802 A PL 01356802A PL 35680201 A PL35680201 A PL 35680201A PL 356802 A1 PL356802 A1 PL 356802A1
Authority
PL
Poland
Prior art keywords
pyrido
pyrimidine
diamine
kinase inhibitors
kinase
Prior art date
Application number
PL01356802A
Other languages
English (en)
Polish (pl)
Inventor
Richard John Booth
Ellen Myra Dobrusin
Vara Prasad Venkata Nagendra Josyula
Dennis Joseph Mcnamara
Peter Laurence Toogood
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of PL356802A1 publication Critical patent/PL356802A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
PL01356802A 2000-01-25 2001-01-23 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors PL356802A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25
PCT/IB2001/000069 WO2001055147A1 (fr) 2000-01-25 2001-01-23 Inhibiteurs de pyrido[2,3-d]pyrimidine-2,7-diamine kinase

Publications (1)

Publication Number Publication Date
PL356802A1 true PL356802A1 (en) 2004-07-12

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01356802A PL356802A1 (en) 2000-01-25 2001-01-23 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors

Country Status (34)

Country Link
EP (1) EP1254137A1 (fr)
JP (1) JP4047010B2 (fr)
KR (1) KR20020065939A (fr)
CN (1) CN1395578A (fr)
AP (1) AP2002002586A0 (fr)
AR (1) AR030044A1 (fr)
AU (1) AU2542501A (fr)
BG (1) BG106850A (fr)
BR (1) BR0107751A (fr)
CA (1) CA2397961C (fr)
CO (1) CO5261549A1 (fr)
CR (1) CR6706A (fr)
CZ (1) CZ20022475A3 (fr)
DZ (1) DZ3266A1 (fr)
EA (1) EA200200643A1 (fr)
EE (1) EE200200405A (fr)
GT (1) GT200100016A (fr)
HN (1) HN2001000013A (fr)
HU (1) HUP0204141A3 (fr)
IL (1) IL150545A0 (fr)
IS (1) IS6443A (fr)
MA (1) MA26868A1 (fr)
MX (1) MXPA02007221A (fr)
NO (1) NO20023527L (fr)
OA (1) OA12161A (fr)
PA (1) PA8510701A1 (fr)
PE (1) PE20011066A1 (fr)
PL (1) PL356802A1 (fr)
SK (1) SK10632002A3 (fr)
SV (1) SV2002000294A (fr)
TN (1) TNSN01014A1 (fr)
WO (1) WO2001055147A1 (fr)
YU (1) YU50402A (fr)
ZA (1) ZA200205879B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AU2002246855B2 (en) 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
KR20040103972A (ko) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
WO2004048343A1 (fr) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Pyrimidines inhibitrices de chk-, pdk- et de akt, production et utilisation de ces composes comme agents pharmaceutiques
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
WO2006032452A1 (fr) * 2004-09-21 2006-03-30 F. Hoffmann-La Roche Ag 6-(2-alkyl-phényl)-pyrido[2,3-d]pyrimidines utiles comme inhibiteurs de la protéine kinase
UY29439A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
JP2008535822A (ja) 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
AU2006229995A1 (en) 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
WO2007009911A1 (fr) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag Composes pyrido [2, 3-d] pyrimidine-2, 4-diamine utilises comme inhibiteurs de ptp1b
AU2006279992A1 (en) * 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (fr) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (fr) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Inhibiteurs Raf améliorés
US8530650B2 (en) * 2008-12-01 2013-09-10 Merck Patent Gmbh 2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
WO2014151682A1 (fr) * 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Composés pyrimidines en tant qu'inhibiteurs de kinase
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
FI971953A7 (fi) * 1994-11-14 1997-05-12 Warner Lambert Co Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6 -aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
DE69939168D1 (de) * 1998-05-26 2008-09-04 Warner Lambert Co Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung

Also Published As

Publication number Publication date
AP2002002586A0 (en) 2002-09-30
PE20011066A1 (es) 2001-10-22
AU2542501A (en) 2001-08-07
CR6706A (es) 2005-04-04
CA2397961C (fr) 2008-08-26
HN2001000013A (es) 2001-06-18
CN1395578A (zh) 2003-02-05
WO2001055147A1 (fr) 2001-08-02
JP2003523357A (ja) 2003-08-05
MXPA02007221A (es) 2002-11-29
BR0107751A (pt) 2002-11-12
JP4047010B2 (ja) 2008-02-13
CO5261549A1 (es) 2003-03-31
EP1254137A1 (fr) 2002-11-06
HUP0204141A2 (hu) 2003-04-28
CA2397961A1 (fr) 2001-08-02
BG106850A (bg) 2003-02-28
YU50402A (sh) 2005-11-28
MA26868A1 (fr) 2004-12-20
PA8510701A1 (es) 2002-12-11
EA200200643A1 (ru) 2002-12-26
HUP0204141A3 (en) 2005-03-29
GT200100016A (es) 2001-10-19
SK10632002A3 (sk) 2003-06-03
ZA200205879B (en) 2003-09-29
EE200200405A (et) 2003-12-15
NO20023527L (no) 2002-09-10
IL150545A0 (en) 2003-02-12
DZ3266A1 (fr) 2001-08-02
NO20023527D0 (no) 2002-07-24
AR030044A1 (es) 2003-08-13
CZ20022475A3 (cs) 2003-03-12
OA12161A (en) 2006-05-08
IS6443A (is) 2002-06-25
SV2002000294A (es) 2002-07-16
TNSN01014A1 (fr) 2005-11-10
KR20020065939A (ko) 2002-08-14

Similar Documents

Publication Publication Date Title
IL150545A0 (en) PYRIDO [2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
HRP20020798A2 (en) 5-ALKYLPYRIDO[2,3-d]PYRIMIDINES TYROZINE KINASE INHIBITORS
IL159832A0 (en) 4-amino-6-phenyl-pyrrolo[2,3-d] pyrimidine derivatives
PL357536A1 (en) Pyrazolo `4,3-d! pyrimidine derivatives
IL181957A0 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
IL153754A0 (en) Pyrimidine derivatives
IL158697A0 (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives
IL148614A0 (en) Pteridinones as kinase inhibitors
AU1041802A (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives
ZA200204510B (en) Imidazopyridine derivatives used as phosphodiesterase VII inhibitors.
DE50001191D1 (de) Pyrazolo[4, 3-d]pyrimidine
PL358551A1 (en) 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines
HRP20030362A2 (en) Pyrimidine derivatives
PL363077A1 (en) Use of pyrazolo[4,3-d]pyrimidines
PL361890A1 (en) Use of pyrazolo[4,3-d]pyrimidines
AU8578501A (en) 2-aminoalkyl-thieno(2,3-d)pyrimidines
IL155380A0 (en) SUBSTITUTED 3,4-DIHYDRO-PYRIDO[1,2-a] PYRIMIDINES
ZA200206528B (en) Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors.
SI1303496T1 (sl) Pirimidinski derivati
IL137434A0 (en) Adjustable deadbolt

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)